Quick Overview
CareLoop, a spinout from the University of Manchester, has successfully raised £1.8 million in seed funding to enhance its digital therapeutics platform aimed at supporting patients with severe mental health conditions.
Key Features of CareLoop’s Platform
- 🔍 Predictive Monitoring: The platform utilizes predictive software to track patients’ wellbeing, enabling clinicians to identify early signs of escalating symptoms.
- 🧠 Targeted Support: CareLoop focuses on severe mental health issues such as psychosis, schizophrenia, and postnatal depression, with plans to expand to bipolar disorder.
- ✅ NICE Approval: The platform has received endorsement from the National Institute for Health and Care Excellence (NICE), validating its effectiveness in managing mental health symptoms.
Funding Details
- The funding round was co-led by the GMC Life Sciences Fund By Praetura and Verge HealthTech Fund.
- Additional contributions came from NPIF II – Praetura Equity Finance and SFC Capital.
Leadership Insights
Zoë Blake, CEO of CareLoop, emphasized the company’s commitment to providing accessible care for those with severe mental illnesses, stating:
“Our mission has always been to provide accessible care where it’s needed to those living with the most severe and enduring mental illnesses.”
Future Plans
- CareLoop aims to broaden its platform to include additional severe mental health conditions.
- The company plans to establish its headquarters in Manchester’s £1.7 billion Sister Innovation District.
Impact on Mental Health Care
- With over a decade of data supporting its approach, CareLoop is poised to enhance mental health support delivery.
- The platform aims to improve the quality of life for millions affected by severe mental health conditions.